Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Beyond clinician support: how to successfully launch paradig...

David Lee and Peter Ehrhardt explore the factors medical technology manufacturers face when pricing paradigm-shifting technologies, looking at past pharma product launches for insights into the current process. Paradigm-shifting technologies, defined as innovations that change the standard of care in a significant way, are the lifeblood of the medical technology industry…

Articles

Personalised medicine: a view from Roche

We interview Dr Horst Kramer of Roche on his definition of personalised medicine, the importance of clear communication in this area and the need for reliable diagnostics. Personalised medicine has received a lot of hype in the media. Over-promising and exaggerations have led to…

Articles

Patient feedback data for health economic modelling: the pat...

DRs Nadine van Dongen explains the importance of the patient’s voice in clinical feedback data and shares her thoughts on the future of health economic evaluations. Up to now, the reimbursement of new innovative pharmaceuticals was merely based on registration data...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.